Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Mol Cancer Ther

Retrieve available abstracts of 24 articles:
HTML format
Text format



Single Articles


    March 2017
  1. WILLUDA J, Linden L, Lerchen HG, Kopitz C, et al
    Preclinical Anti-Tumor Efficacy of BAY 1129980 - a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-small Cell Lung Cancer.
    Mol Cancer Ther. 2017 Mar 14. pii: molcanther.0474.2016.
    PubMed     Text format     Abstract available


    February 2017
  2. HUSAIN H, Scur M, Murtuza A, Bui N, et al
    Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer.
    Mol Cancer Ther. 2017;16:265-272.
    PubMed     Text format     Abstract available


    January 2017
  3. NANJO S, Arai S, Wang W, Takeuchi S, et al
    MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer.
    Mol Cancer Ther. 2017 Jan 30. pii: molcanther.0522.2016.
    PubMed     Text format     Abstract available


    December 2016
  4. KOBAYASHI Y, Azuma K, Nagai H, Kim YH, et al
    Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer.
    Mol Cancer Ther. 2016 Dec 2. pii: molcanther.0407.2016.
    PubMed     Text format     Abstract available


    November 2016
  5. NAKAMURA Y, Weaver Ohler Z, Householder D, Nagaya T, et al
    Near infrared photoimmunotherapy in a transgenic mouse model of spontaneous epidermal growth factor receptor (EGFR)-expressing lung cancer.
    Mol Cancer Ther. 2016 Nov 15. pii: molcanther.0663.2016.
    PubMed     Text format     Abstract available


    August 2016
  6. XU X, Mao L, Xu W, Tang W, et al
    AC0010, an irreversible EGFR inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance in animal models and lung cancer patients.
    Mol Cancer Ther. 2016 Aug 29. pii: molcanther.0281.2016.
    PubMed     Text format     Abstract available


  7. DANILOV AV, Hu S, Orr B, Godek K, et al
    Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin Dependent Kinases 1 and 2.
    Mol Cancer Ther. 2016 Aug 22. pii: molcanther.0127.2016.
    PubMed     Text format     Abstract available


    July 2016
  8. MCLAUGHLIN KA, Nemeth Z, Bradley CA, Humphreys L, et al
    FLIP: a targetable mediator of resistance to radiation in non-small cell lung cancer.
    Mol Cancer Ther. 2016 Jul 29. pii: molcanther.0211.2016.
    PubMed     Text format     Abstract available


    May 2016
  9. JHURANEY A, Woods NT, Wright G, Rix L, et al
    PAXIP1 potentiates the combination of WEE1 inhibitor AZD1775 and platinum agents in lung cancer.
    Mol Cancer Ther. 2016 May 11. pii: molcanther.0182.2015.
    PubMed     Text format     Abstract available


    February 2016
  10. WAN L, Sun M, Liu GJ, Wei CC, et al
    Long non-coding RNA PVT1 promotes non-small cell lung cancer cell proliferation through epigenetically regulating LATS2 expression.
    Mol Cancer Ther. 2016 Feb 23. pii: molcanther.0707.2015.
    PubMed     Text format     Abstract available


  11. JANG JY, Kim YG, Nam SJ, Keam B, et al
    Targeting adenine nucleotide translocase-2 (ANT2) to overcome resistance to epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer.
    Mol Cancer Ther. 2016 Feb 16. pii: molcanther.0089.2015.
    PubMed     Text format     Abstract available


  12. ONION D, Argent RH, Reece-Smith AM, Craze ML, et al
    3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal cells but Sensitivity to Histone Deacetylase Inhibitors.
    Mol Cancer Ther. 2016 Feb 12. pii: molcanther.0598.2015.
    PubMed     Text format     Abstract available


  13. FENG J, Zhang S, Wu K, Wang B, et al
    Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-small-cell Lung Cancer.
    Mol Cancer Ther. 2016 Feb 2. pii: molcanther.0445.2015.
    PubMed     Text format     Abstract available


    January 2016
  14. LI J, Fang B, Kinose F, Bai Y, et al
    Target identification in small cell lung cancer via integrated phenotypic screening and activity-based protein profiling.
    Mol Cancer Ther. 2016 Jan 15. pii: molcanther.0444.2015.
    PubMed     Text format     Abstract available


    December 2015
  15. TANI T, Yasuda H, Hamamoto J, Kuroda A, et al
    Activation of EGFR bypass signaling by TGFalpha overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells.
    Mol Cancer Ther. 2015 Dec 18. pii: molcanther.0084.2015.
    PubMed     Text format     Abstract available


  16. ZUBOVYCH IO, Sethi A, Kulkarni A, Tagal V, et al
    A Novel Inhibitor Of Topoisomerase I is Selectively Toxic For A Subset of Non-Small Cell Lung Cancer Cell Lines.
    Mol Cancer Ther. 2015 Dec 14. pii: molcanther.0458.2015.
    PubMed     Text format     Abstract available


  17. ALHAKAMY NA, Ishiguro S, Uppalapati D, Berkland CJ, et al
    AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray.
    Mol Cancer Ther. 2015 Dec 4. pii: molcanther.0448.2015.
    PubMed     Text format     Abstract available


    September 2015
  18. SUGANO T, Seike M, Noro R, Soeno C, et al
    Inhibition of ABCB1 Overcomes Cancer Stem Cell-like Properties and Acquired Resistance to MET inhibitor in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2015 Sep 8. pii: molcanther.0050.2015.
    PubMed     Text format     Abstract available


    August 2015
  19. LENHART R, Kirov S, Desilva H, Cao J, et al
    Sensitivity of Small-Cell Lung Cancer to BET Inhibition is Mediated by Regulation of ASCL1 Gene Expression.
    Mol Cancer Ther. 2015 Aug 7. pii: molcanther.0037.2015.
    PubMed     Text format     Abstract available


    July 2015
  20. CUMMINGS CT, Zhang W, Davies KD, Kirkpatrick GD, et al
    Small molecule inhibition of MERTK is efficacious in non-small cell lung cancer models independent of driver oncogene status.
    Mol Cancer Ther. 2015 Jul 10. pii: molcanther.0116.2015.
    PubMed     Text format     Abstract available


    May 2015
  21. BONELLI MA, Cavazzoni A, Saccani F, Alfieri RR, et al
    Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations.
    Mol Cancer Ther. 2015 May 26. pii: molcanther.0892.2014.
    PubMed     Text format     Abstract available


    March 2015
  22. NAKANISHI Y, Akiyama N, Tsukaguchi T, Fujii T, et al
    Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1.
    Mol Cancer Ther. 2015;14:704-12.
    PubMed     Text format     Abstract available


    January 2015
  23. OHKUBO S, Kodama Y, Muraoka H, Hitotsumachi H, et al
    TAS-116, a highly selective inhibitor of heat shock protein 90alpha and beta, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models.
    Mol Cancer Ther. 2015;14:14-22.
    PubMed     Text format     Abstract available


  24. ZHANG Z, Zhang Y, Sun Q, Feng F, et al
    Preclinical pharmacokinetics, tolerability, and pharmacodynamics of metuzumab, a novel CD147 human-mouse chimeric and glycoengineered antibody.
    Mol Cancer Ther. 2015;14:162-73.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: